Therapy resistance in leukemia may be due to cancer cell-intrinsic and/or -extrinsic mechanisms. Mutations within BCR-ABL1, the oncogene giving rise to chronic myeloid leukemia (CML), lead to resistance to tyrosine kinase inhibitors (TKI), and some are associated with clinically more aggressive disease and worse outcome. Using the retroviral transduction/transplantation model of CML and human cell lines we faithfully recapitulate accelerated disease course in TKI resistance. We show in various models, that murine and human imatinib-resistant leukemia cells positive for the oncogene BCR-ABL1T315I differ from BCR-ABL1 native (BCR-ABL1) cells with regards to niche location and specific niche interactions. We implicate a pathway via integrin β3, integrin-linked kinase (ILK) and its role in deposition of the extracellular matrix (ECM) protein fibronectin as causative of these differences. We demonstrate a trend towards a reduced BCR-ABL1T315I+ tumor burden and significantly prolonged survival of mice with BCR-ABL1T315I+ CML treated with fibronectin or an ILK inhibitor in xenogeneic and syngeneic murine transplantation models, respectively. These data suggest that interactions with ECM proteins via the integrin β3/ILK-mediated signaling pathway in BCR-ABL1T315I+ cells differentially and specifically influence leukemia progression. Niche targeting via modulation of the ECM may be a feasible therapeutic approach to consider in this setting.
Resistance to cancer treatments may be due to cancer cell-intrinsic mechanisms, such as alteration of the drug target, deregulation of (anti-) apoptotic pathways, drug inactivation or shuttling of the drug out of the cancer cell [1,2,3]. Cancer cell-extrinsic mechanisms of chemoresistance may be mediated by alterations of drug binding to plasma proteins or their catabolism or the tumor microenvironment . However, whether leukemia cell-intrinsic mutations conferring resistance to therapy lead to differential interactions with the bone marrow (BM) microenvironment (BMM), a complex arrangement of various cell types, extracellular matrix (ECM) proteins, and other factors , has not been shown.
The BCR-ABL1 oncogene, generated by the translocation between chromosomes 9 and 22, results in deregulated activity of the BCR-ABL1 tyrosine kinase driving chronic myeloid leukemia (CML) at early disease stages . BCR-ABL1 is targeted by tyrosine kinase inhibitors (TKIs) . However, resistance to TKIs such as imatinib may occur due to the BCR-ABL1T315I and other mutations [8, 9]. BCR-ABL1T315I arises in the ABL kinase domain interfering with binding to TKIs like imatinib and others [8, 9] accounting for 15–20% of mutations found in CML patients [10, 11]. Patients with imatinib resistance due to BCR-ABL1T315I have a rapid clinical course and poor prognosis [11,12,13], although other mechanisms may be contributory . In the case of BCR-ABL1T315I kinase activity does not correlate with increased transformation potency [15, 16]. Global phosphoproteome analysis of BCR-ABL1T315I+ cells identified a unique signature of phosphosubstrates compared with cells positive for native BCR-ABL1 or other imatinib-resistance conferring mutations leading to altered biological properties . However, exactly how these leukemia cell-intrinsic alterations might influence disease outcome, for instance via altered interactions with the BMM, has not been demonstrated.
Niche occupation in the BMM by normal hematopoietic stem and progenitor cells (HSPC)  or leukemic stem cells (LSC) in acute myeloid leukemia (AML)  depends on their maturation stage or the state of disease progression, respectively. We hypothesized that differences in clinical outcome of patients with CML due to imatinib-resistant mutations in BCR-ABL1 may correlate with LSC location in the BMM and specific interactions with the BMM. Indeed, here we show that interactions of leukemic murine and human cells with the BMM via the fibronectin/integrin β3/integrin-linked kinase (ILK)-mediated signaling pathway influence leukemia progression and clinical outcome in BCR-ABL1T315I+ imatinib-resistant CML in vivo. Targeting these interactions may offer a beneficial, innovative, additive treatment strategy for patients with BCR-ABL1T315I+ CML, and possibly other leukemias.
Materials and methods
All statistical analyses were performed using GraphPad Prism software. Survival curves were analyzed by Kaplan–Meier-style curves and Log-rank (Mantel–Cox) or Gehan–Breslow–Wilcoxon tests. Differences between groups were assessed by student’s t-test. When multiple hypotheses were tested, one-way ANOVA and a Tukey test were used as post-hoc test. The data were presented as mean ± s.d. P values ≤ 0.05 were considered significant.
BCR-ABL1T315I+ differ from BCR-ABL1+ cells with regards to diverse biological functions
To test the location of CML-initiating cells (LIC) in the BMM, we performed in vivo confocal 2-photon microscopy of the murine calvarium. Measuring the shortest three-dimensional distance to the endosteum , we demonstrated that transplanted BCR-ABL1+ Lin− c-Kit+ Sca-1+ (LKS) cells, which harbor the LSC  in the retroviral transduction/transplantation model of CML , and, particularly, LKS CD150+ CD48− (SLAM) cells, were located significantly further away from the endosteum than control cells (P = 0.0029 and P = 0.0035, respectively, Figs. 1a, S1A and Supplementary Table 1). Prior in vitro treatment of BCR-ABL1+ LKS cells with imatinib led to closer localization of imatinib-treated LKS cells to the endosteum (P = 0.003, Figs. 1b and S1B). However, BCR-ABL1T315I+ LIC, which are resistant to all TKIs apart from ponatinib and the allosteric inhibitor of the ABL1 kinase, asciminib , localized closer to osteoblastic cells than BCR-ABL1+ LKS cells (P < 0.0001, Fig. 1c). We tested whether murine recipients of BM transduced with BCR-ABL1, BCR-ABL1T315I, BCR-ABL1M351T, BCR-ABL1Y253F, or BCR-ABL1E255K (the latter both P-loop mutations) [20, 22] may recapitulate the accelerated disease course in patients. Indeed, the survival of untreated recipients of BCR-ABL1T315I− or BCR-ABL1Y253F− transduced BM was significantly shortened compared with recipients of BCR-ABL1+ or BCR-ABL1M351T+ BM (Fig. 1d). Consistent with increased engraftment of BCR-ABL1T315I+ proviral clones and more aggressive disease of BCR-ABL1T315I+ CML [20, 23], the disease clonality was significantly higher in recipients of BCR-ABL1T315I+ than BCR-ABL1+ BM (P = 0.035, Fig. 1e, f). CML was detectable 8 days after transplantation (Fig. S1C–D), and the leukocyte count was higher in recipients of BCR-ABL1T315I+ than BCR-ABL1+ BM (P = 0.0335, Fig. 1g). Similar to human imatinib-resistant patients with BCR-ABL1T315I+ disease, blasts were increased in the peripheral blood (Fig. S1E) and the BM of mice with BCR-ABL1T315I+ CML (Fig. 1h, i). GFP+ (BCR-ABL1+ or BCR-ABL1T315I+) Gr-1+ (Fig. 1j) and in particular GFP+ CD11bmedium+ (Figs. 1k and S1F) myeloid cells, which likely represent the blasts (Fig. 1l), were higher in mice with BCR-ABL1T315I+ than BCR-ABL1+ CML. BCR-ABL1T315I+ CD11bmedium+ cells expressed the highest levels of c-Kit (P < 0.0001, Fig. S1G), but lower levels of myeloperoxidase (P = 0.0121, Fig. S1H–I). Overall, a decrease of the percentage of GFP+ c-Kit+ cells (P = 0.0095, Fig. 1m) and an increase of GFP+ CD34+ (P = 0.0003, Fig. S2A) and GFP+ CD13+ (P = 0.0019, Fig. S2B) cells were observed in mice with BCR-ABL1T315I+ CML. The frequency of BCR-ABL1T315I+ (GFP+) LKS cells (P = 0.0045, Fig. S2C) and myeloid progenitor cells (Fig. S2D) in the BM were reduced. However, the percentage of BCR-ABL1T315I+ (GFP+) LKS SLAM did not differ compared with BCR-ABL1+ CML (Fig. S2E). Concordant with decreased myeloid maturation expression of the myeloid transcription factor Cebpa in total BM cells of mice with BCR-ABL1T315I+ CML was significantly decreased (P = 0.03, Fig. 1n and Supplementary Table 2). There was a trend toward reduced expression of Spi1 (PU.1), another myeloid transcription factor, in BCR-ABL1T315I+ cells (Fig. S2F). The migration of BCR-ABL1T315I+ BA/F3 cells (P = 0.0267, Fig. 1o), a frequently used in vitro model [24, 25], and the adhesion of BCR-ABL1T315I+ CD11b+ cells to the stroma cell line MS-5 in vitro (P = 0.0063, Fig. 1p) were significantly increased compared with BCR-ABL1+ BA/F3 cells. In summary, these findings suggest that BCR-ABL1+ and BCR-ABL1T315I+ leukemia cells differ with respect to homing localization in the BMM, migration, adhesion, disease aggressiveness and (immuno-) phenotype.
The actin cytoskeleton and expression and function of focal adhesion kinase differ between BCR-ABL1T315I+ and BCR-ABL1+ cells
We hypothesized that differences in the actin cytoskeleton and/or focal adhesion kinase (FAK) , which is phosphorylated by BCR-ABL1 , underlie the increased migration (Fig. 1o) and adhesion (Fig. 1p) of BCR-ABL1T315I+ cells. Indeed, immunofluorescence staining of 3T3 fibroblasts, frequently used as model system to visualize the actin cytoskeleton in BCR-ABL1+ cells [28, 29], revealed that the evenly distributed and polymerized actin cytoskeleton in empty vector-transduced 3T3 cells was less finely arranged in BCR-ABL1+ and decreased in BCR-ABL1T315+ 3T3 cells (Figs. 2a and S3A). Staining of FAK, a focal adhesion protein involved in actin polymerization  and cytoskeletal stability , which lies downstream of the integrin receptors, in 3T3 cells transduced with empty vector-expressing retrovirus, was punctate, possibly consistent with an intact focal adhesosome. However, the punctae were reduced in BCR-ABL1+ and completely dispersed and granular in BCR-ABL1T315I+ 3T3 cells (P < 0.0001; Fig. 2b, c). Phosphorylation at phosphotyrosine pY397 in FAK, an autophosphorylation site , was higher in BCR-ABL1+ compared with BCR-ABL1T315I+ BA/F3 (Figs. 2d, e and S3B) and Lin− cells (Fig. S3C), while phosphorylation at pY925 was similar. shRNA-mediated knockdown of Ptk2 (FAK) (Fig. S3D) or the gene of another adapter protein at focal adhesion sites, paxillin (Pxn), (Fig. S3E) in BCR-ABL1+ or BCR-ABL1T315I+ donor BM did not lead to survival prolongation in recipient wildtype mice. Taken together, these data suggest that the cytoskeleton differs between BCR-ABL1+ versus BCR-ABL1T315I+ cells. Possibly due to differing phosphorylation of FAK by BCR-ABL1 versus BCR-ABL1T315I focal adhesions may be dysfunctional in BCR-ABL1T315I+ cells.
Integrin β3 expression on BCR-ABL1T315I+ cells influences CML progression
Given our above observations, the known involvement of pY397 of FAK for FAK-mediated cell migration and the phosphorylation of FAK at pY397 upon clustering of integrins , we assessed expression of various integrins. While there was no difference in mean fluorescence intensity of integrin α5 (CD49e) (Fig. S4A), integrin α IIb (CD41), which forms a heterodimer with integrin β3 , was less expressed on BCR-ABL1T315I+ compared with BCR-ABL1+ cells (P = 0.0103, Fig. S4B). Further, integrin β3, previously implicated in the development and progression of AML , was more highly expressed on BCR-ABL1T315I+ versus BCR-ABL1+ or empty vector-transduced BA/F3 cells by immunoblotting (Figs. 3a and S4C) and super-resolution microscopy  (P = 0.0228, Figs. 3b and S4D). Primary Gr-1+ BCR-ABL1T315I+ myeloid cells (P = 0.0306, Fig. 3c) and total GFP+ BM cells (P = 0.0021, Fig. 3d) from CML mice also revealed significantly increased expression of integrin β3. This was also independently confirmed using stable isotope labeling with amino acids in cell culture-based quantitative mass spectrometry (Fig. S4E, Supplementary Table 3). Consistently, coimmunoprecipitation of BA/F3 cells transduced with BCR-ABL1 or BCR-ABL1T315I with an antibody to integrin β3 revealed increased binding of FAK to integrin β3 in BCR-ABL1T315I+ cells (Fig. S4F). Exogenous overexpression of integrin β3 on BCR-ABL1+ or BCR-ABL1T315I+ donor BM by retroviral cotransduction  (Fig. S3G), led to significantly reduced leukocyte counts in peripheral blood (P = 0.0031 for BCR-ABL1+ and P < 0.0001 for BCR-ABL1T315I+, Fig. 3e) and prolonged survival (P = 0.0018 for BCR-ABL1+ and P = 0.0025 for BCR-ABL1T315I+, Fig. 3f) in most recipients of integrin β3+ compared with empty vector-transduced BCR-ABL1+ or BCR-ABL1T315I+ donor BM. Homing of empty vector- or integrin β3-overexpressing LIC did not differ (Fig. S4H–I). In contrast, knockdown of integrin β3 on BCR-ABL1+ or BCR-ABL1T315I+ donor BM did not alter survival (Fig. S4J–K). Testing phagocytic activity, characteristic of mature myeloid cells, we demonstrated that` phagocytosis was significantly reduced in BCR-ABL1T315I+ versus BCR-ABL1+ myeloid cells (P = 0.0256, Fig. 3g). However, overexpression of integrin β3 on BCR-ABL1T315I+ myeloid cells ‘rescued’ or restored the phagocytosis of bacterial particles (P = 0.0418, Fig. 3g). In summary, these data suggested that integrin β3 plays a role in the outcome of, particularly, BCR-ABL1T315I+ CML, while also influencing the differentiation of BCR-ABL1+ and BCR-ABL1T315I+ myeloid cells.
Fibronectin is decreased in the BMM of mice with BCR-ABL1T315I+ CML
Next, we tested the adhesion of empty vector-, BCR-ABL1- or BCR-ABL1T315I+ primary BM cells to the ECM protein fibronectin, one of the ligands of integrin β3. This revealed increased adhesion of BCR-ABL1T315I+ cells to fibronectin compared with empty vector- or BCR-ABL1-transduced cells (P < 0.0001, Fig. 4a). We hypothesized that BCR-ABL1T315I+ CML cells, similar to other cancers , may deposit less fibronectin. Indeed, 3T3 fibroblasts transduced with BCR-ABL1T315I deposited significantly less fibronectin than BCR-ABL1+ fibroblasts (Fig. S5A). Deposition of fibronectin was kinase-dependent, as treatment of BCR-ABL1+, BCR-ABL1Y253F+, or BCR-ABL1T315I+ 3T3 fibroblasts with the TKI ponatinib significantly increased fibronectin deposition, while imatinib had no effect on imatinib-resistant BCR-ABL1 mutants (Fig. 4b). Less fibronectin was also found in the BMM of mice with CML due to BCR-ABL1T315I, BCR-ABL1E255K, or BCR-ABL1Y253F, but not BCR-ABL1M351T compared with control mice (Figs. 4c and S5B). In order to test whether the generation of fibronectin by leukemia cells influences leukemia progression and accelerates BCR-ABL1+ CML similar to BCR-ABL1T315I+ CML, we transduced the BM of fibronectin flox/flox × Mx1-Cre (FN Mx1-Cre) mice with BCR-ABL1 or BCR-ABL1T315I, before transplantation into wildtype recipients and subsequent administration of poly I:C to induce Cre (Fig. S5C). This led to a significant increase of the number of leukocytes in the peripheral blood of mice that had received BCR-ABL1+ FN Mx1-Cre BM (P = 0.0403, Fig. 4d) and significant shortening of survival of those mice which received BCR-ABL1+ (P = 0.0162, Fig. 4e) or BCR-ABL1T315I+ FN Mx1-Cre BM compared with their respective controls (P = 0.0018, Fig. S5D). All mice succumbed to CML-like disease. Later deletion of fibronectin in LIC had the same effect (Fig. 4f, g). In contrast, no effect on survival was observed when BCR-ABL1+ or BCR-ABL1T315I+ wildtype BM was transplanted into fibronectin flox/flox × Col1a2-Cre (FN Col1a2-Cre) mice (Fig. S5E–F), characterized by lack of production of fibronectin by fibroblasts . In summary, these data suggest that BCR-ABL1T315I+ CML cells produce less fibronectin than BCR-ABL1+ cells and that fibronectin production by leukemia cells influences CML progression.
Integrin-linked kinase is involved in fibronectin deposition and influences survival in BCR-ABL1T315I+ CML
Hypothesizing that BCR-ABL1T315I+ leukemia cells deposit less fibronectin than BCR-ABL1+ leukemia cells due to differences in signaling pathways, we focused on ILK, a pseudokinase belonging to the family of RAF-like kinases involved in integrin-mediated signal transduction  and fibronectin deposition [38, 39]. ILK is linked to the cytoplasmic domains of integrins β1 and β3 . We demonstrated that levels of total ILK and ILK phosphorylated at its autophosphorylation site S246 (ILK pS246) were increased in BCR-ABL1T315I+ compared with BCR-ABL1+ BA/F3 (Figs. 5a and S6A–B) or Lin− cells (Fig. S6C–D). Treatment with ponatinib reduced levels of ILK, and ILK pS246 in BCR-ABL1+ and BCR-ABL1T315I+ BA/F3 cells, suggesting that protein levels of ILK and possibly phosphorylation of ILK may be BCR-ABL1-dependent (Figs. 5b and S6E–F), though not directly mediated by the tyrosine kinase BCR-ABL1. ILK and integrin β3 colocalized in BCR-ABL1+ and BCR-ABL1T315I+ BA/F3 cells, but the staining pattern for ILK and integrin β3 was more diffuse and less punctate in BCR-ABL1T315I+ compared with BCR-ABL1+ cells (Figs. 5c and S6G). Consistently, in spite of the overexpression of integrin β3, binding between ILK and integrin β3 was reduced in BCR-ABL1T315I+ compared with BCR-ABL1+ cells (Figs. 5d and S6H). Cotransduction of donor BM with BCR-ABL1- versus BCR-ABL1T315I-expressing retrovirus and scrambled- or Ilk shRNA-expressing lentivirus (P = 0.0133, Fig. S6I) led to a significant reduction of leukocyte counts (P = 0.0018, Fig. 5e) and significant prolongation of survival (P = 0.0476, Figs. 5f and S6I) in recipients of BCR-ABL1T315I+ sh Ilk+ donor BM compared with controls, also when knockdown of Ilk was induced at a later timepoint after transplantation (P = 0.0028, Figs. 5g and S6J). Knockdown of Ilk also led to an increase in fibronectin deposition by BCR-ABL1T315I+ sh Ilk+ 3T3 fibroblasts (Fig. 5h) and in the BMM of recipients of BCR-ABL1T315I+ sh Ilk+ donor BM compared with controls (Figs. 5i and S6K). As BCR-ABL1 only phosphorylates tyrosine and not serine residues, we tested the phosphorylation of ILK at pS246 after treatment of BCR-ABL1T315I+ BA/F3 cells with vehicle, the ILK inhibitor Cpd22, ponatinib or the phosphoinositide-3-kinase (PI3K) inhibitor wortmannin, as PI3K is activated by BCR-ABL1 . This revealed that levels of pS246ILK were decreased by Cpd22, ponatinib, and wortmannin, while total ILK was mostly decreased by ponatinib (Figs. 5j and S6L–M), suggesting that PI3K may differentially phosphorylate ILK in BCR-ABL1+ versus BCR-ABL1T315I+ cells. Taken together, these data suggest that binding between ILK and integrin β3 is impaired in BCR-ABL1T315I+ cells and that ILK plays an important role in progression of BCR-ABL1T315I+ CML, at least partly via modulation of fibronectin levels in the BMM.
Treatment with fibronectin prolongs survival in BCR-ABL1T315I+ CML
Hypothesizing that replenishing reduced fibronectin levels in mice with BCR-ABL1T315I+ CML may decelerate leukemia progression, we transplanted LIC, resuspended in vehicle or fibronectin, intrafemorally into mice as proof of principle. This plus two further intrafemoral applications of fibronectin led to a significant reduction of leukocytes in peripheral blood (P = 0.0096; Fig. 6a) and significant survival prolongation (P = 0.0246; Fig. 6b) in mice with BCR-ABL1T315I+ CML compared with controls. Intravenous administration of fibronectin also significantly prolonged the survival of mice with BCR-ABL1T315I+ CML (P = 0.017; Fig. 6c) and increased fibronectin levels in the BM (Fig. S7A). However, administration of fibronectin to mice with BCR-ABL1+ B-cell acute lymphoblastic leukemia (Fig. S7B)  or MLL-AF9+ AML (Fig. S7C) [20, 42] did not lead to significant differences in survival. Taken together, these data suggest that fibronectin may be involved in regulating the progression of BCR-ABL1T315I+ CML.
Treatment with the ILK inhibitor Cpd22 and ponatinib prolongs survival in BCR-ABL1T315I+ CML
In order to test whether inhibition of ILK may have a role for the treatment of BCR-ABL1T315I+ CML, we treated mice with BCR-ABL1T315I+ CML with vehicle, ponatinib, the ILK inhibitor Cpd22 , or the combination of Cpd22 and ponatinib. Cotreatment with the ILK inhibitor Cpd22 and ponatinib led to a modest, but significant prolongation of survival compared with treatment with ponatinib alone (P = 0.0036; Fig. 7a). Consistent with a presumed role of ILK in fibronectin deposition, treatment with Cpd22 alone, ponatinib alone, or the combination of Cpd22 and ponatinib increased the levels of fibronectin in bone sections (Fig. 7b). Treatment with Cpd22 or ponatinib increased the percentage of integrin β3+ BCR-ABL1+ (Fig. S8A) and BCR-ABL1T315I+ (Fig. S8B) cells. Integrin β3 clusters per area, which fortify the interaction with focal adhesosomes , also significantly increased by treatment of BCR-ABL1T315I+ cells with Cpd22 (P = 0.0051, Fig. S8C). In summary, inhibition of ILK with Cpd22 in combination with ponatinib prolongs survival in BCR-ABL1T315I+ CML. The benefit of ILK inhibition may lie in the combination of increasing fibronectin levels in the BMM, as well as in the further increase of integrin β3 on leukemia cells.
The fibronectin/integrin β3/ILK-axis in human BCR-ABL1T315I+ CML cells
Validating our results in the human setting, we demonstrated increased levels of integrin β3 (P = 0.025, Figs. 7c and S8D–E), increased migration (P = 0.0439, Fig. 7d) and adhesion of K562T315I (P = 0.0288, Fig. 7e) compared with K562 cells . Transplantation of K562 versus K562T315I cells into NOD SCID interleukin-2 receptor γ (NSG) knockout mice led to increased percentages of human CD45+ leukocytes in peripheral blood (P = 0.0133, Fig. 7f) and BM (P = 0.0357, Fig. 7g) in recipients of K562T315I cells. Similar, but less striking results were observed after transplantation of KCL-22T315I compared with KCL-22 cells (Fig. S8F–G). Treatment of NSG mice transplanted with K562T315I cells with Cpd22, ponatinib or their combination led to a trend towards reduced engraftment of human CD45+ leukocytes compared with vehicle (Figs. 7h and S8H). Furthermore, fibronectin levels were significantly reduced in bone sections (P = 0.043; Fig. 7i, j) and levels of ILK, ILK pS246 and integrin β3 were higher in leukemia cell samples from most patients with BCR-ABL1T315I+ compared with BCR-ABL1+ CML, though inter-patient variability was observed (Figs. 7k and S8I). Lastly, transplantation of human BCR-ABL1+ versus BCR-ABL1T315I+ CML cells into NSG mice treated in pairs with vehicle or fibronectin led to a nonsignificant reduction of the engraftment of human CD45+ leukocytes in the majority of treated versus untreated mouse pairs (Fig. 7l). Treatment with fibronectin also led to a reduction of oncogene transcript levels in 2/4 (50%) recipients of human BCR-ABL1+ and 4/5 (80%) recipients of BCR-ABL1T315I+ CML cells (Fig. 7m). In summary, our data with human material suggest that the described link between fibronectin/integrin β3/ILK may also be applicable to human BCR-ABL1T315I+ CML.
In continuation of previous studies [15, 16] we demonstrate here that the increased oncogenicity of the BCR-ABL1T315I mutation is at least partly due to differences in the interaction with the BMM and its remodeling compared with native BCR-ABL1. BCR-ABL1T315I+ cells differ from BCR-ABL1+ cells with regards to the actin cytoskeleton, migratory properties, expression of integrin β3, the levels and phosphorylation of FAK and ILK, as well as ILK-dependent deposition of fibronectin in the BMM. Further increased expression of integrin β3 led to increased myeloid maturation and a deceleration of leukemic progression, while a decrease of fibronectin expression in BCR-ABL1+ cells accelerated the disease similar to BCR-ABL1T315I+ CML. Administration of fibronectin decelerated BCR-ABL1T315I+ disease. In summary, our data suggest that interactions with proteins of the ECM influence CML progression and that therapeutic manipulation of the levels of ECM proteins may be beneficial in (resistant) CML.
Our data extend the observation that integrin β3 is essential for leukemogenesis and influences outcome in AML  and suggest that integrin β3—possibly via its interaction with ECM proteins such as fibronectin—may be involved in myeloid maturation, as suggested for integrin β1 .
Our findings on the differential location of normal HSPC and BCR-ABL1+ or BCR-ABL1T315I+ LIC are consistent with a previous study on the distinct physical engagement of the BMM by MLL-AF9+ AML cells, which is dependent on the degree of leukemic progression . Our results further suggest that niche location of malignant cells may influence survival, possibly also in response to TKI treatment.
The involvement of ILK in the pathophysiology of BCR-ABL1T315I+ (and BCR-ABL1+) CML, given its linkage to the cytoplasmic domains of integrin β1 and β3, its support of scaffolding proteins  and its known role in the deposition of fibronectin by epithelial cells —though opposite from our results in hematopoietic cells—and other ECM proteins  was not surprising and may be context dependent. The expression and activity of ILK is known to be increased in several epithelial cancers , where it may also contribute to chemoresistance via regulation of adhesion to fibronectin . In addition, ILK has been postulated to be a novel target in solid cancers  and leukemia , though a connection to the BMM was not established. In our work, treatment with Cpd22 and ponatinib significantly prolonged survival in BCR-ABL1T315I+ CML compared with ponatinib alone.
Fibronectin is overexpressed in certain cancers and contributes to the tumorigenic process  contrary to our findings in BCR-ABL1T315I+ CML, where decreased levels of fibronectin exacerbate leukemia progression. In hematopoiesis, fibronectin supports the growth of HSPC [53, 54], whereas fibronectin may inhibit the proliferation of B-ALL cells in vitro . Our data suggest that administration of fibronectin—or an increase of fibronectin levels via inhibition of ILK—may be beneficial in BCR-ABL1T315I+ CML, for which limited therapies or only treatments with significant side effects exist. Although fibronectin did not lead to a significant survival prolongation in BCR-ABL1+ B-ALL or MLL-AF9+ AML, it is likely that this may have been due to suboptimal dosing and timing of the administration of fibronectin, whose high purchasing costs were prohibitive of further exploration in this study.
In conclusion, we have demonstrated that a point mutation in the kinase domain of BCR-ABL1, which leads to imatinib resistance, in our models has altered biological activity and is associated with more aggressive disease due to altered interactions with the BMM via the fibronectin-integrin β3-ILK pathway. We confirmed altered, though variable expression levels and targetability of these proteins in human BCR-ABL1T315I+ CML cells. This may also explain the accelerated phenotype in humans. These altered interactions and specifically decreased levels of fibronectin or ILK in BCR-ABL1T315I+ CML are valuable targets. It is to be hoped that modification of this pathway will lead to the development of novel therapies for imatinib-resistant CML and, hopefully, other leukemias.
Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275–84.
Zheng HC. The molecular mechanisms of chemoresistance in cancers. Oncotarget. 2017;8:59950–64.
Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353:172–87.
Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501:346–54.
Krause DS, Scadden DT. A hostel for the hostile: the bone marrow niche in hematologic neoplasms. Haematologica. 2015;100:1376–87.
Soverini S, Mancini M, Bavaro L, Cavo M, Martinelli G. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer. 2018;17:49.
Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Druker BJ, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100–4.
Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876–80.
Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2:117–25.
Soverini S, Branford S, Nicolini FE, Talpaz M, Deininger MW, Martinelli G, et al. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res. 2014;38:10–20.
Nicolini FE, Corm S, Lê QH, Sorel N, Hayette S, Bories D, et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(ϕ)-LMC GROUP). Leukemia. 2006;20:1061–6.
Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood. 2009;114:5426–35.
Nicolini FE, Ibrahim AR, Soverini S, Martinelli G, Müller MC, Hochhaus A, et al. The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis. Haematologica. 2013;98:1510–6.
Balabanov S, Braig M, Brümmendorf TH. Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia. Drug Discov Today Technol. 2014;11:89–99.
Skaggs BJ, Gorre ME, Ryvkin A, Burgess MR, Xie Y, Han Y, et al. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci USA. 2006;103:19466–71.
Griswold IJ, MacPartlin M, Bumm T, Goss VL, O’Hare T, Lee KA, et al. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol. 2006;26:6082–93.
Lo Celso C, Fleming HE, Wu JW, Zhao CX, Miake-Lye S, Fujisaki J, et al. Live-animal tracking of individual haematopoietic stem cells in their niche. Nature. 2009;457:92–6.
Lane SW, Wang YJ, Lo Celso C, Ragu C, Bullinger L, Sykes SM, et al. Differential niche and Wnt requirements during acute myeloid leukemia progression. Blood. 2011;118:2849–56.
Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci USA. 2006;103:16870–5.
Krause DS, Fulzele K, Catic A, Sun CC, Dombkowski D, Hurley MP, et al. Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nat Med. 2013;19:1513–7.
Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017;543:733–7.
Li S, Ilaria RL, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med. 1999;189:1399–412.
Krause DS, Lazarides K, von Andrian UH, Van Etten RA. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med. 2006;12:1175–80.
Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, et al. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood. 2012;119:1501–10.
Nardi V, Naveiras O, Azam M, Daley GQ. ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines. Blood. 2009;113:3813–20.
Cheng K, Kurzrock R, Qiu X, Estrov Z, Ku S, Dulski KM, et al. Reduced focal adhesion kinase and paxillin phosphorylation in BCR-ABL-transfected cells. Cancer. 2002;95:440–50.
Gotoh A, Miyazawa K, Ohyashiki K, Tauchi T, Boswell HS, Broxmeyer HE, et al. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein. Exp Hematol. 1995;23:1153–9.
Van Etten RA, Jackson P, Baltimore D. The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell. 1989;58:669–78.
Weisberg E, Sattler M, Ewaniuk DS, Salgia R. Role of focal adhesion proteins in signal transduction and oncogenesis. Crit Rev Oncog. 1997;8:343–58.
Roa-Espitia AL, Hernández-Rendón ER, Baltiérrez-Hoyos R, Muñoz-Gotera RJ, Cote-Vélez AIJ, et al. Focal adhesion kinase is required for actin polymerization and remodeling of the cytoskeleton during sperm capacitation. Biol Open. 2016;5:1189–99.
Fabry B, Klemm AH, Kienle S, Schäffer TE. WHG Focal adhesion kinase stabilizes the cytoskeleton. Biophys J. 2011;101:2131–8.
Parsons JT. Focal adhesion kinase: the first ten years. J Cell Sci. 2003;116:1409–16.
Corbel C, Vaigot P, Salaün J. (alpha)IIb Integrin, a novel marker for hemopoietic progenitor cells. Int J Dev Biol. 2005;49:279–84.
Miller PG, Al-Shahrour F, Hartwell KA, Chu LP, Jaras M, Puram RV, et al. In vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell. 2013;24:45–58.
Sauer M, Heilemann M. Single-molecule localization microscopy in eukaryotes. Chem Rev. 2017;117:7478–509.
Kawelke N, Vasel M, Sens C, Au A, Dooley S, Nakchbandi IA. Fibronectin protects from excessive liver fibrosis by modulating the availability of and responsiveness of stellate cells to active TGF-β. PLoS ONE. 2011;6:e28181.
Ghatak S, Morgner J, Wickström SA. ILK: a pseudokinase with a unique function in the integrin-actin linkage. Biochem Soc Trans. 2013;41:995–1001.
Guo L, Wu C. Regulation of fibronectin matrix deposition and cell proliferation by the PINCH-ILK-CH-ILKBP complex. FASEB J. 2002;16:1298–1300.
Gagné D, Groulx JF, Benoit YD, Basora N, Herring E, Vachon PH, et al. Integrin-linked kinase regulates migration and proliferation of human intestinal cells under a fibronectin-dependent mechanism. J Cell Physiol. 2010;222:387–400.
Widmaier M, Rognoni E, Radovanac K, Azimifar SB, Fässler R. Integrin-linked kinase at a glance. J Cell Sci. 2012;125:1839–43.
Kharas MG, Janes MR, Scarfone VM, Lilly MB, Knight ZA, Shokat KM, et al. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Investig. 2008;118:3038–50.
Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006;442:818–22.
Ahmed AU, Yim HCH, Alorro M, Ernst M, Williams BRG. Integrin-linked kinase expression in myeloid cells promotes inflammatory signaling during experimental colitis. J Immunol. 2017; pii: ji1700125. https://doi.org/10.4049/jimmunol.1700125. [Epub ahead of print].
Kim SH, Turnbull J, Guimond S. Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J Endocrinol. 2011;209:139–51.
Tamai M, Inukai T, Kojika S, Abe M, Kagami K, Harama D, et al. T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR/Cas9 system. Sci Rep. 2018;8:9966.
Kerst JM, Sanders JB, Slaper-Cortenbach IC, Doorakkers MC, Hooibrink B, van Oers RH, et al. Alpha 4 beta 1 and alpha 5 beta 1 are differentially expressed during myelopoiesis and mediate the adherence of human CD34+ cells to fibronectin in an activation-dependent way. Blood. 1993;81:344–51.
Wu C, Keightley SY, Leung-Hagesteijn C, Radeva G, Coppolino M, Goicoechea S, et al. Integrin-linked protein kinase regulates fibronectin matrix assembly, E-cadherin expression, and tumorigenicity. J Biol Chem. 1998;273:528–36.
Morgner J, Ghatak S, Jakobi T, Dieterich C, Aumailley M, Wickström SA. Integrin-linked kinase regulates the niche of quiescent epidermal stem cells. Nat Comm. 2015;8:8198.
Hannigan G, Troussard AA, Dedhar S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer. 2005;5:51–63.
Nakagawa Y, Nakayama H, Nagata M, Yoshida R, Kawahara K, Hirosue A, et al. Overexpression of fibronectin confers cell adhesion-mediated drug resistance (CAM-DR) against 5-FU in oral squamous cell carcinoma cells. Int J Oncol. 2014;44:1376–84.
de la Puente P, Weisberg E, Muz B, Nonami A, Luderer M, Stone RM, et al. Identification of ILK as a novel therapeutic target for acute and chronic myeloid leukemia. Leuk Res. 2015; pii: S0145-2126(15)30377-5. https://doi.org/10.1016/j.leukres.2015.09.005. [Epub ahead of print].
Wang JP, Hielscher A. Fibronectin: how its aberrant expression in tumors may improve therapeutic targeting. J Cancer. 2017;8:674–82.
Williams DA, Rios M, Stephens C, Patel VPFibronectin. and VLA-4 in haematopoietic stem cell-microenvironment interactions. Nature. 1991;352:438–41.
Yokota T, Oritani K, Mitsui H, Aoyama K, Ishikawa J, Sugahara H, et al. Growth-supporting activities of fibronectin on hematopoietic stem/progenitor cells in vitro and in vivo: structural requirement for fibronectin activities of CS1 and cell-binding domains. Blood. 1998;91:3263–72.
Włodek J, Pituch-Noworolska A. The influence of fibronectin on proliferation and apoptosis of acute lymphoblastic leukaemia cells in vitro. Pol J Pathol. 2018;69:62–6.
Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99:319–25.
The authors thank Joel A. Spencer, Cristina Lo Celso, and Charles P. Lin for assistance with in vivo microscopy. This work was supported by the LOEWE Center for Cell and Gene Therapy Frankfurt (CGT) and institutional funds of the Georg-Speyer-Haus to DSK. The Georg-Speyer-Haus is funded jointly by the German Federal Ministry of Health (BMG) and the Ministry of Higher Education, Research and the Arts of the State of Hessen (HMWK). The LOEWE Center for Cell and Gene Therapy Frankfurt is funded by HMWK, reference number: III L 4-518/17.004 (2010).
Conflict of interest
RK, MeMe, and DSK hold patent no. WO2018/046666 for the use of fibronectin and ILK-inhibitors in leukemia.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Kumar, R., Pereira, R.S., Zanetti, C. et al. Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia. Leukemia 34, 2087–2101 (2020). https://doi.org/10.1038/s41375-020-0866-1
Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021
“Caught in the net”: the extracellular matrix of the bone marrow in normal hematopoiesis and leukemia
Experimental Hematology (2020)
The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase
Leukemia Research (2020)